Spyre Therapeutics, Inc. (SYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put SYRE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisManagement screens weak on capital allocation, margins.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 28% in its worst 12-month stretch.
View RiskSpyre Therapeutics must keep its recent performance steady to justify its price. The company is unprofitable, so its value rests on future growth. Revenue growth is not accelerating, and the latest quarter beat expectations. The stock trades at 603 times sales versus a 9 times peer median. This massive premium means the market expects significant future success. The price is roughly in line with the growth we forecast. A public offering could dilute financial strength and challenge the thesis. Peer multiples imply a price about 8% above where it trades. This read is provisional.
Trailing returns as of 2026-11-04. SYRE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering SYRE (as of Nov 2026).
Based on 8 Wall Street analysts offering 12-month price targets for SYRE in the last 4 months.
Continue this research
Compare SYRE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SYRE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SYRE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Public offering may dilute financial strength.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $99.04
The last 12 months of price, then the range of analyst 12-month targets from today’s $99.04.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Advance Phase 2 SKYLINE and SKYWAY trials with multiple proof-of-concept readou…
Positive trial data supports advancement of Phase 2 trials.

Threatens: Focus on long-acting antibodies for IBD and rheumatic diseases
Mixed results may hinder long-acting antibody focus.

Threatens: Advance Phase 2 SKYLINE trial for SPY001
Stock tumble indicates investor concern over trial outcomes.

Analyst maintains buy rating, supporting positive outlook.